Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Protein in the urine (proteinuria) and Steroid-resistant nephrotic syndrome; and common findings: Stage 5 chronic kidney disease and Focal segmental glomerulosclerosis.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Kidneys and urinary system | 4 | Stage 5 chronic kidney disease, Focal segmental glomerulosclerosis, Protein in the urine (proteinuria) |
TBC1D8B function has not been fully characterized.
Nephrotic syndrome, type 20 has been associated with mutations in the TBC1D8B gene on chromosome X.
Genetic testing for TBC1D8B is available. Testing is considered supportive for diagnosis.
Biomarker and diagnostic research for nephrotic syndrome, type 20 has been reported in the published literature.
Phenotype severity distribution: 2 always present features, 2 common features.
No clinical trials have been registered for nephrotic syndrome, type 20.
42 publications have been identified in PubMed for nephrotic syndrome, type 20. Research spans Case Report / Case Series (31%), Epidemiology / Natural History (21%), and Clinical Trial Publication (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 13 | 31% |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 1:02 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Disease patterns and progression
9 |
21% |
Clinical study results | 7 | 17% |
Laboratory research | 6 | 14% |
Testing and diagnosis research | 2 | 5% |
Research summaries | 2 | 5% |
New treatment approaches | 2 | 5% |
Other research | 1 | 2% |
Ma Y (2026). [PMID: 42063792](https://pubmed.ncbi.nlm.nih.gov/42063792/). *Front Med (Lausanne)*. [Case Report / Case Series]
Kunisho Y (2026). [PMID: 41642467](https://pubmed.ncbi.nlm.nih.gov/41642467/). *CEN case reports*. [Case Report / Case Series]
Zhao X (2026). [PMID: 41756365](https://pubmed.ncbi.nlm.nih.gov/41756365/). *Frontiers in medicine*. [Other]
Gopal M (2026). [PMID: 42005116](https://pubmed.ncbi.nlm.nih.gov/42005116/). *Cureus*. [Epidemiology / Natural History]
Leon J (2026). [PMID: 41692345](https://pubmed.ncbi.nlm.nih.gov/41692345/). *Kidney international*. [Basic Science / Preclinical]
Maekawa S (2026). [PMID: 41999621](https://pubmed.ncbi.nlm.nih.gov/41999621/). *Nephron*. [Case Report / Case Series]
Meena P (2026). [PMID: 41703478](https://pubmed.ncbi.nlm.nih.gov/41703478/). *BMC Nephrol*. [Epidemiology / Natural History]
Bhaumik A (2026). [PMID: 42078290](https://pubmed.ncbi.nlm.nih.gov/42078290/). *Cureus*. [Epidemiology / Natural History]
Sampath Kumar D (2026). [PMID: 41782702](https://pubmed.ncbi.nlm.nih.gov/41782702/). *Clinical nephrology. Case studies*. [Epidemiology / Natural History]
Lu S (2026). [PMID: 41759264](https://pubmed.ncbi.nlm.nih.gov/41759264/). *International immunopharmacology*. [Case Report / Case Series]